Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.28%
#4 aPriori aPriori +133.46%
#5 Bedrock Bedrock +71.29%
#6 Cysic Cysic +49.09%
#7 Prom Prom +41.40%
#8 Playnance Playnance +35.05%
#9 COTI COTI +29.45%
#10 Bitway Bitway +24.50%
Coin of the day
Wrapped One Wrapped One
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Kedudukan dalam Saham #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Harga Saham
$0.0009
Disegerakkan terakhir: 2025-05-27
Modal Pasaran
$1.15K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Arch Therapeutics, Inc. (ARTH)

Kategori

Healthcare
Nisbah P/E bagi Arch Therapeutics, Inc. (ARTH)
Nisbah P/E pada August 2026 TTM: 0.00
Menurut laporan kewangan dan harga saham terkini Arch Therapeutics, Inc., nisbah P/E semasa (TTM) ialah 0.00. Pada akhir 2022, syarikat mempunyai nisbah P/E sebanyak -1.08.
Sejarah nisbah P/E bagi Arch Therapeutics, Inc. dari 2011 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 0.00 -100.00%
2023 -0.57 -46.88%
2022 -1.08 -75.26%
2021 -4.35 -99.73%
2020 -1.62K -44.60%
2019 -2.93K 15.52%
2018 -2.54K -14.51%
2017 -2.97K 7.68%
2016 -2.76K 88.35%
2015 -1.46K 390.49%
2014 -298.39 -75.27%
2013 -1.21K -57.39%
2012 -2.83K -93.43%
2011 -43.07K 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.